# Appendices

[← Previous: References](11-references.md) | [Back to Main](../README.md)

---

## Appendix A: Abbreviations

| Abbreviation | Full Term |
|--------------|-----------|
| ASM | Antiseizure Medication |
| BID | Twice daily |
| BRV | Brivaracetam |
| CAE | Childhood Absence Epilepsy |
| CBZ | Carbamazepine |
| CLB | Clobazam |
| CrCl | Creatinine Clearance |
| DRE | Drug-Resistant Epilepsy |
| DRESS | Drug Reaction with Eosinophilia and Systemic Symptoms |
| ESL | Eslicarbazepine |
| ESM | Ethosuximide |
| FBM | Felbamate |
| GBP | Gabapentin |
| GTC | Generalized Tonic-Clonic |
| HD | Hemodialysis |
| JME | Juvenile Myoclonic Epilepsy |
| LCM | Lacosamide |
| LEV | Levetiracetam |
| LFT | Liver Function Tests |
| LTG | Lamotrigine |
| MCM | Major Congenital Malformations |
| NDD | Neurodevelopmental Disorders |
| OXC | Oxcarbazepine |
| PB | Phenobarbital |
| PE | Phenytoin Equivalents |
| PER | Perampanel |
| PGB | Pregabalin |
| PHT | Phenytoin |
| PRM | Primidone |
| QHS | At bedtime |
| QOD | Every other day |
| RUF | Rufinamide |
| SE | Status Epilepticus |
| SJS | Stevens-Johnson Syndrome |
| TEN | Toxic Epidermal Necrolysis |
| TID | Three times daily |
| TPM | Topiramate |
| UGT | UDP-Glucuronosyltransferase |
| VGB | Vigabatrin |
| VPA | Valproate/Valproic Acid |
| ZNS | Zonisamide |

---

## Appendix B: Evidence Levels

| Level | Description | Requirements |
|-------|-------------|--------------|
| **Level A** | Established as effective/ineffective | ≥2 Class I studies |
| **Level B** | Probably effective/ineffective | 1 Class I or ≥2 Class II studies |
| **Level C** | Possibly effective/ineffective | 1 Class II or ≥2 Class III studies |
| **Level U** | Data inadequate or conflicting | Insufficient evidence |

### Study Classification

| Class | Description |
|-------|-------------|
| **Class I** | Randomized, controlled clinical trial with masked outcome assessment, in a representative population |
| **Class II** | Randomized, controlled trial in a representative population with masked outcome assessment but one of the following limitations: (a) primary outcome is not blinded, (b) protocol violation, (c) crossover design |
| **Class III** | Controlled studies (including well-designed natural history controls) |
| **Class IV** | Uncontrolled studies, case series, case reports, expert opinion |

---

## Appendix C: ASM Mechanisms of Action

| Mechanism | ASMs | Notes |
|-----------|------|-------|
| **Voltage-gated Na+ channel blockade** | CBZ, OXC, PHT, LCM, LTG, ZNS, ESL | May worsen absence/myoclonic |
| **Enhanced slow inactivation of Na+ channels** | LCM | Unique mechanism |
| **T-type Ca2+ channel blockade** | ESM, ZNS | Effective for absence |
| **High-voltage Ca2+ channel modulation** | GBP, PGB | α2δ subunit binding |
| **GABA-A receptor modulation** | PB, BZDs, CLB | Sedation, tolerance risk |
| **GABA transaminase inhibition** | VGB | Irreversible; visual field risk |
| **GAT-1 inhibition** | Tiagabine | GABA reuptake |
| **SV2A binding** | LEV, BRV | Novel mechanism |
| **AMPA receptor antagonism** | PER | Adjunctive therapy |
| **Multiple mechanisms** | VPA, TPM, FBM | Broad-spectrum |
| **Carbonic anhydrase inhibition** | TPM, ZNS | Metabolic acidosis risk |

---

## Appendix D: Brand Names Reference

| Generic Name | Common Brand Names |
|--------------|-------------------|
| Brivaracetam | Briviact |
| Carbamazepine | Tegretol, Carbatrol, Epitol |
| Clobazam | Onfi, Sympazan |
| Eslicarbazepine | Aptiom |
| Ethosuximide | Zarontin |
| Felbamate | Felbatol |
| Gabapentin | Neurontin, Gralise |
| Lacosamide | Vimpat |
| Lamotrigine | Lamictal |
| Levetiracetam | Keppra, Roweepra |
| Oxcarbazepine | Trileptal, Oxtellar |
| Perampanel | Fycompa |
| Phenobarbital | Luminal |
| Phenytoin | Dilantin, Phenytek |
| Pregabalin | Lyrica |
| Primidone | Mysoline |
| Rufinamide | Banzel |
| Topiramate | Topamax, Trokendi |
| Valproate | Depakote, Depakene, Epilim |
| Vigabatrin | Sabril, Vigadrone |
| Zonisamide | Zonegran |

---

## Appendix E: Pregnancy Category Summary

| Category | ASM | MCM Risk | Recommendation |
|----------|-----|----------|----------------|
| **Preferred** | Levetiracetam | 2-3% | First choice in pregnancy |
| **Preferred** | Lamotrigine | 2-3% | First choice; monitor levels |
| **Acceptable** | Oxcarbazepine | 2-3% | Alternative option |
| **Caution** | Carbamazepine | 4-6% | NTD risk; avoid if possible |
| **Avoid** | Topiramate | 3-5% | Oral clefts, ID risk |
| **Contraindicated** | Valproate | 5-15% | 30-40% NDD risk; never in pregnancy |

---

## Appendix F: Quick Dosing Reference Card

### Adults - Common ASMs

| ASM | Start | Target | Max |
|-----|-------|--------|-----|
| LEV | 500 mg BID | 1500 mg BID | 3000 mg/day |
| LTG | 25 mg daily | 200 mg BID | 600 mg/day |
| VPA | 250 mg BID | 750 mg BID | 60 mg/kg/day |
| CBZ | 200 mg BID | 600 mg BID | 1600 mg/day |
| OXC | 300 mg BID | 900 mg BID | 2400 mg/day |
| LCM | 50 mg BID | 150 mg BID | 400 mg/day |
| TPM | 25 mg daily | 150 mg BID | 400 mg/day |
| ZNS | 100 mg daily | 300 mg daily | 600 mg/day |

### Status Epilepticus

| Line | Agent | Dose |
|------|-------|------|
| 1st | Lorazepam IV | 0.1 mg/kg (max 4 mg) |
| 1st | Midazolam IM | 10 mg (adults) |
| 2nd | Fosphenytoin | 20 mg PE/kg |
| 2nd | Valproate | 40 mg/kg |
| 2nd | Levetiracetam | 60 mg/kg |

---

## Appendix G: Contact Information

### Professional Organizations

| Organization | Website |
|--------------|---------|
| International League Against Epilepsy (ILAE) | [ilae.org](https://www.ilae.org) |
| American Epilepsy Society (AES) | [aesnet.org](https://www.aesnet.org) |
| Epilepsy Foundation | [epilepsy.com](https://www.epilepsy.com) |
| American Academy of Neurology (AAN) | [aan.com](https://www.aan.com) |

### Poison Control / Drug Information

| Resource | Contact |
|----------|---------|
| US Poison Control | 1-800-222-1222 |
| FDA MedWatch | [fda.gov/medwatch](https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program) |

---

*This protocol is intended as a clinical reference and should be used in conjunction with clinical judgment and individual patient assessment. Always consult current prescribing information and local formulary guidelines.*

**Document Control:**
- Version: 1.0
- Created: December 2025
- Review Date: December 2026
- Author: Clinical Protocol Development

---

[← Previous: References](11-references.md) | [Back to Main](../README.md)
